NOVO-B Stock Analysis: Novo Nordisk | CO
Drug Manufacturers - General | CO, Denmark | Market Cap: 1.427.919m DKK | 12M Return: -24.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.10B
EPS Trend: 89.1%
Qual. Beats: 1
Rev. Trend: 97.0%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. It operates through two business segments: Obesity and Diabetes Care, which focuses on diabetes, obesity, cardiovascular, and emerging therapy areas; and Rare Disease, which addresses rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The companys product portfolio includes smart insulin pens (NovoPen 6 and NovoPen Echo Plus), the Dose Check insulin dose guidance application, growth hormone pens, injection needles, and Wegovy, an oral GLP-1 receptor agonist therapy for weight management. Novo Nordisk distributes its products globally across Europe, North America, Asia, Latin America, the Middle East, and Africa.
As a large-cap biotechnology company in the healthcare sector, Novo Nordisks business model is centered on the research, development, manufacture, and distribution of prescription pharmaceuticals, with revenue heavily dependent on patented therapies in the GLP-1 drug class and rare disease treatments. The pharmaceutical industry is characterized by high R&D investment, long product development cycles, and reliance on regulatory approvals and intellectual property protection.
- Wegovy and Ozempic demand drives obesity segment growth
- Eli Lilly Zepbound competition pressures GLP-1 market share
- US Medicare pricing negotiations threaten diabetes margins
| Net Income: 122b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -9.73 > 1.0 |
| NWC/Revenue: -14.59% < 20% (prev -20.36%; Δ 5.77% < -1%) |
| CFO/TA 0.21 > 3% & CFO 119b > Net Income 122b |
| Net Debt (133b) to EBITDA (178b): 0.75 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.45b) vs 12m ago 0.05% < -2% |
| Gross Margin: 81.85% > 18% (prev 84.33%; Δ -2.48% > 0.5%) |
| Asset Turnover: 62.53% > 50% (prev 61.97%; Δ 0.56% > 0%) |
| Interest Coverage Ratio: 7.36 > 6 (EBIT TTM 161b / Interest Expense TTM 21.8b) |
| A: -0.09 (Total Current Assets 177b - Total Current Liabilities 225b) / Total Assets 559b |
| B: 0.37 (Retained Earnings 206b / Total Assets 559b) |
| C: 0.31 (EBIT TTM 161b / Avg Total Assets 524b) |
| D: 0.57 (Book Value of Equity 203b / Total Liabilities 356b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 1.07 (Receivables 100b/86.4b, Revenue 328b/303b) |
| GMI: 1.03 (GM 84.33% / 81.85%) |
| AQI: 0.99 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 1.08 (Revenue 328b / 303b) |
| TATA: 0.01 (NI 122b - CFO 119b) / TA 559b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at DKK 326.50 with a total of 2,873,640 shares traded. Over the past week, the price has changed by -0.46%, over one month by +3.68%, over three months by +23.91% and over the past year by -24.26%.
Current recommended Stop Loss: 312.40 (which is 4.3% or 1.5 ATR below the current price).
Novo Nordisk has no consensus analysts rating.
P/E Trailing = 11.7743
P/E Forward = 14.8368
P/S = 4.3561
P/B = 7.1456
P/EG = 3.3774
Revenue TTM = 328b DKK
EBIT TTM = 161b DKK
EBITDA TTM = 178b DKK
Long Term Debt = 119b DKK (from longTermDebt, last quarter)
Short Term Debt = 27.2b DKK (from shortTermDebt, last quarter)
Debt = 155b DKK (from shortLongTermDebtTotal, last quarter) + Leases 8.57b
Net Debt = 133b DKK (calculated: Debt 155b - CCE 21.6b)
Enterprise Value = 1561b DKK (1428b + Debt 155b - CCE 21.6b)
Interest Coverage Ratio = 7.36 (Ebit TTM 161b / Interest Expense TTM 21.8b)
EV/FCF = 50.32x (Enterprise Value 1561b / FCF TTM 31.0b)
FCF Yield = 1.99% (FCF TTM 31.0b / Enterprise Value 1561b)
FCF Margin = 9.47% (FCF TTM 31.0b / Revenue TTM 328b)
Net Margin = 37.20% (Net Income TTM 122b / Revenue TTM 328b)
Gross Margin = 81.85% ((Revenue TTM 328b - Cost of Revenue TTM 59.5b) / Revenue TTM)
Gross Margin QoQ = 85.96% (prev 80.86%)
Tobins Q-Ratio = 2.79 (Enterprise Value 1561b / Total Assets 559b)
Interest Expense / Debt = 14.09% (Interest Expense 21.8b / Debt 155b)
Taxrate = 21.66% (33.7b / 156b)
NOPAT = 126b (EBIT 161b * (1 - 21.66%))
Current Ratio = 0.79 (Total Current Assets 177b / Total Current Liabilities 225b)
Debt / Equity = 0.76 (Debt 155b / totalStockholderEquity, last quarter 203b)
Debt / EBITDA = 0.75 (Net Debt 133b / EBITDA 178b)
Debt / FCF = 4.30 (Net Debt 133b / FCF TTM 31.0b)
Total Stockholder Equity = 184b (last 4 quarters mean from totalStockholderEquity)
RoA = 23.27% (Net Income 122b / Total Assets 559b)
RoE = 66.36% (Net Income TTM 122b / Total Stockholder Equity 184b)
RoCE = 53.07% (EBIT 161b / Capital Employed (Equity 184b + L.T.Debt 119b))
RoIC = 36.52% (NOPAT 126b / Invested Capital 345b)
WACC = 9.46% (E(1428b)/V(1583b) * Re(9.29%) + D(155b)/V(1583b) * Rd(14.09%) * (1-Tc(0.22)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -78.40 | Cagr: -0.10%
[DCF] Terminal Value 69.05% ; FCFF base≈48.5b ; Y1≈42.5b ; Y5≈34.4b
[DCF] Fair Price = 99.50 (EV 466b - Net Debt 133b = Equity 333b / Shares 3.35b; r=9.46% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 89.10 | EPS CAGR: 16.58% | SUE: 3.17 | # QB: 1
Revenue Correlation: 97.01 | Revenue CAGR: 19.23% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=4.97 | Chg30d=-3.94% | Revisions=-50% | Analysts=7
EPS next Quarter (2026-09-30): EPS=4.88 | Chg30d=-2.43% | Revisions=-17% | Analysts=6
EPS current Year (2026-12-31): EPS=21.01 | Chg30d=+0.04% | Revisions=-21% | GrowthEPS=-8.8% | GrowthRev=-4.9%
EPS next Year (2027-12-31): EPS=21.50 | Chg30d=-0.36% | Revisions=+13% | GrowthEPS=+2.3% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -16% (up=12, down=17)